Kornimate/medical-research-clean huggingface dataset:
regulation of different it on vascular function of overweight female university students

Conditions: Overweight

Summary: this study investigates the effects of different interval training methods, specifically high-intensity interval training (hiit) and sprint interval training (sit), on vascular function in overweight female university students. a randomized controlled trial was conducted over an 8-week period.

this study aimed to evaluate how different types of interval training (hiit and sit) influence vascular function in overweight female university students. participants were initially enrolled and randomly assigned to hiit, sit, or control groups. the participants in hiit and sit groups underwent an 8-week supervised exercise program 3 times per week on a treadmill. both pre- and post-intervention measurements were taken, including vascular function, morphological indicators, and blood markers. this study highlights the potential of interval training as a time-efficient and effective intervention for improving cardiovascular health and body composition in this population.

Eligibility criteria:
inclusion criteria: * participants aged between 18 and 25 years, female. * participants' bmi more than 24 kg·m-2. * participants without regular exercise habits. exclusion criteria: * participants underwent other interventions (e.g., nutrition, psychology, exercise, health education, et al). * participants had a history of systematic and professional exercise habit. * participants presenced of disease or condition restricting participation, such as injuries, respiratory disease or cardiovascular diseases.

Keywords: high intensity interval training sprint interval training overweight female vascular function
a randomized clinical trial evaluating plaque removal around dental implants

Conditions: Peri Implantitis

Summary: this aim of this study is to compare different oral hygiene aids for the ability to remove plaque in patients who went through dental implant treatment and are currently on a maintenance program at the graduate periodontal clinic, at the university of manitoba, faculty of dentistry.

home care and oral hygiene regimes are as well an important aspect of short and long term dental implant survival and success. the investigators profession demands us to educate the patients about the risk of peri implantitis and peri mucositis in plaque infected dentitions. in periodontal patients the areas of most ineffective plaque removal are typically the palatal/lingual and interdental areas. there is therefore a need to developing scientific evidence to form a framework for professionals to follow when educating patients about their home care.

Eligibility criteria:
inclusion criteria: * non smokers, with clinical probing depth around implants is less than or equal to 6mm and are currently maintained every 3 months at the graduate periodontal program exclusion criteria: * smokers * probing depth 6 or \> 6mm * non compliant patients and patients with severe systemic conditions

Keywords: plaque removal around dental implants
hip viscosupplementation: what is the best dosage?

Conditions: Osteoarthritis

Summary: intraarticular injections have long been used to treat osteoarthritis. viscosupplementation is a relatively new approach comprising the injection of hyaluronic acid into diarthrodial joints. the dosis regimen is well established for the knee joint, but there is still no consensus regarding the optimal dosage for hip viscosupplementation. our objective is to determine the optimal dosis for hip viscosupplementation

intraarticular injections have long been used to treat osteoarthritis. viscosupplementation is a relatively new approach comprising the injection of hyaluronic acid into diarthrodial joints. any osteoarthritic joint is eligible to this treatment modality, but the great majority of studies are for knee viscosupplementation. the dosis regimen is well established for the knee joint, but there is still no consensus regarding the optimal dosage for hip viscosupplementation. we will prospectively enroll 80 patients with hip osteoarthritis and will randomize them into four groups: group zero will receive joint lavage with saline injection. group 1 will receive joint lavage with saline injection and 2 ml of hylan gf-20 (1 ampoule of synvisc classic®). group 2 will receive joint lavage with saline injection and 4 ml of hylan gf-20 (2 ampoules of synvisc classic®). group 3 will receive joint lavage with saline injection and 6 ml of hylan gf-20 (3 ampoules of synvisc classic®). the visual analogic scale of pain (vas), the western ontario and mcmaster universities index (womac®), and lequesne questionnaires were completed at baseline and at weeks 1, 4, 12, and 24. our objective is to determine the optimal dosis for hip viscosupplementation

Eligibility criteria:
inclusion criteria: * met the american college of rheumatology criteria for hip osteoarthritis * no hip intraarticular injections in the last 6 months exclusion criteria: - severe reaction to the procedure

Keywords: osteoarthritis hip viscosupplementation clinical trial
a study to evaluate the safety of tralokinumab in adults and adolescents with uncontrolled asthma

Conditions: Inadequately Controlled Asthma

Summary: a 52-week, open-label, multicentre study to evaluate the safety of tralokinumab in japanese adults and adolescents with asthma inadequately controlled on inhaled corticosteroid plus long-acting β2-agonist

this is a 52-week, open-label, multi-centre study designed to evaluate the safety of tralokinumab in a fixed 300 mg dose every 2 weeks, administered subcutaneously in adults and adolescents with indequately controlled asthma on medium to high dose inhaled corticosteroid plus long acting β-2 antagonist. approximately 26 japanese subjects will be recruited to receive 22 completed.

Eligibility criteria:
inclusion criteria: 1. age 12 - 75 yrs 2. documented physician-diagnosed asthma 3. documented treatment with inhaled corticosteroid (ics) at a total daily dose corresponding to ≥500 µg fluticasone propionate dry powder formulation equivalents and a long-acting beta-2 agonist (laba) 4. pre-bronchodilator (bd) forced expiratory volume at one second (fev1) value of ≥40% of their predicted normal value (pnv) 5. asthma control questionnaire-6 (acq-6) score ≥1.5 exclusion criteria: 1. pulmonary disease other than asthma 2. history of anaphylaxis following any biologic therapy 3. hepatitis b, c or hiv 4. pregnant of breastfeeding 5. history or cancer 6. current tobacco smoking or a history or tobacco smoking for ≥10 pack-years 7. previous receipt of tralokinumab

Keywords: open-label study tralokinumab subcutaneous inadequately controlled asthma asthma medium to high-dose of inhaled corticosteroid long-acting β2-agonist
a study of arry-371797 in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this is a phase 1 study, involving a 29-day treatment period, designed to evaluate the pharmacokinetics and the effectiveness of investigational study drug arry-371797 in treating rheumatoid arthritis in patients receiving stable doses of methotrexate, and to further evaluate the drug's safety. approximately 30 patients from the us will be enrolled in this study.


Eligibility criteria:
key inclusion criteria: * diagnosed with rheumatoid arthritis (ra) at least 3 months prior to study start based upon the american college of rheumatology (acr) 1987 revised criteria. * on a stable weekly dose of both methotrexate (mtx) (10 - 25 mg/week inclusively; either oral or parenteral) and folate (≥ 5 mg weekly ) for ≥ 6 weeks prior to study start and is willing to continue on these regimens for the duration of the study. * meets the acr 1991 revised criteria for global functional status in ra, class i, ii, or iii. * completed an appropriate washout period if treated with specified therapies. * patients may continue on specified stable background therapy for ra (doses should be stable for at least 6 weeks prior to the first dose of study drug, unless the patient stops due to documented disease improvement, with sponsor approval). * additional criteria exist. key exclusion criteria: * diagnosis of any other inflammatory or non-inflammatory arthritis (e.g. spondyloarthritis; fibromyalgia, psoriatic arthritis, crystal-proven gout) that may interfere with disease activity assessments and/or clinically apparent osteoarthritis which would affect subsequent efficacy measures. * has received any of the following prior treatments: 1. within 4 weeks of first dose of study drug: anakinra (kineret®), etanercept (enbrel®); 2. within 8 weeks of first dose of study drug: infliximab (remicade®), adalimumab (humira®), leflunomide (arava®); 3. at any time: rituximab (rituxan®), alemtuzumab (campath®), any experimental b cell targeting agents. * treatment with potent cyp3a inhibitors or inducers, disease-modifying antirheumatic drugs (dmards) and/or biologic response modifiers (brms) during the study. * additional criteria exist.
perimodiolar implant performance in adults with low-frequency residual hearing

Conditions: Sensorineural Hearing Loss; Low-Frequency Residual Hearing

Summary: the purpose of the feasibility study is to investigate hearing performance (audiometry and speech perception) using the ci632 in a group of adults (n=15) with low-frequency residual hearing who meet inclusion criteria.


Eligibility criteria:
inclusion criteria: 1. 18 years-of-age or older at the time of surgery. 2. low-frequency threshold at 500 hz ≤ 50 db hl and high-frequency pure-tone average (pta), 2000-8000 hz ≥ 65 db hl in the ear to be implanted. 3. pure-tone average (pta) (0.5k, 1k, 2k hz) \> 30 db hl in the contralateral ear. 4. cnc word recognition scores (mean of two lists) ≤ 60% in the ear to be implanted and ≤ 80% in the contralateral ear. 5. english spoken as a primary language. 6. willing and able to provide written informed consent. exclusion criteria: 1. individuals greater than or equal to 70 years at the time of surgery. 2. duration of severe to profound sensorineural hearing loss \> 20 years per self-report. 3. onset of sensorineural hearing loss, for the purpose of this study, prior to 5 years-of-age. 4. ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array. 5. conductive overlay of 15 db or greater at two or more frequencies, in the range of 250 through 1000 hz in the ear to be implanted. 6. hearing loss of neural or central origin. 7. diagnosis of auditory neuropathy. 8. active middle-ear infection. 9. medical or psychological conditions that contraindicate undergoing surgery as determined by the investigator. 10. unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the device and/or procedure, as determined by the investigator. 11. additional handicaps that would prevent or restrict participation in the audiological evaluations as determined by the investigator. 12. unable or unwilling to comply with the requirements of the clinical investigation as determined by the investigator. 13. investigator site personnel directly affiliated with this study and/or their immediate family (spouse, parent, child, or sibling). 14. cochlear employees or employees of a contract research organization (cro) or contractors engaged by cochlear for the purposes of this investigation. 15. currently participating, or has participated in the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device.
early maladaptative schemas among euthymic patients with bipolar disorder in the versailles fondamental advanced centers of expertise for bipolar disorders cohort

Conditions: Bipolar Disorder

Summary: early maladaptive schemas (ems) are overactivated in euthymic bipolar disorders (bd) and are associated with poor psychosocial functioning and higher suicidality. the first objective of this study is to establish different clusters of ems in euthymic bipolar disorders, compare these clusters according to the clinical characteristics of bd and neuropsychological performances and evaluate the temporal stability of these clusters at 12 and 24 months. the second objective of this study is to quantify the impact of ems on functioning in euthymic bd, beyond the effect of cognition and residual depressive symptoms.

early maladaptive schemas (ems) are overactivated in euthymic bipolar disorders (bd) and are associated with poor psychosocial functioning and higher suicidality. however, few studies have explored ems in bipolar disorders, despite ems therapy is a promising tool for the psychotherapy of bd. this study will use the data collected at the versailles expert center for bipolar disorder, in the local face-bd registry. these data will be collected at the inclusion, 12 months and 24 months later. they included an extensive neuropsychological battery and an extensive evaluation of the clinical characteristics of bipolar disorder. ems will be measured with the young schema questionnaire short form 3. the first objective of this study is to establish different clusters of ems in euthymic bipolar disorders, compare these clusters according to the clinical characteristics of bd and neuropsychological performances and evaluate the temporal stability of these clusters at 12 and 24 months. the second objective of this study is to quantify the impact of ems on functioning in euthymic bd, beyond the effect of cognition and residual depressive symptoms.

Eligibility criteria:
inclusion criteria: - bipolar disorder according to dsm iv-r (structured clinical interview) exclusion criteria: * major depressive or manic or hypomanic during the evaluation * montgomery åsberg depression rating scale ⩽10 * young mania rating scale ⩽12

Keywords: early maladaptative schemas cognition functioning
fractional co2 laser delivery of topical insulin versus platelet rich plasma in treatment of atrophic post acne scars

Conditions: Acne Vulgaris

Summary: compare the efficacy and safety of treating atrophic post acne scars with topical insulin versus platelet rich plasma prp combined with fractional ablative co2 laser

acne vulgaris is a common cutaneous inflammatory disorder of the pilosebaceous unit, which runs a chronic course. the condition commonly manifests with papules, pustules, or nodules primarily on the face, although it can also affect the upper arms, trunk, and back. the pathogenesis of acne vulgaris involves the interaction of multiple factors that ultimately lead to the formation of its primary lesion, which is known as "comedo". because of its long duration and exposure to affected areas, acne is associated with a major deterioration in a patient's quality of life and well-being . up to 95% of acne sufferers have some degree of acne scarring, with 30% reporting severe acne scarring. scarring from acne is common when medical care is delayed or is not sufficient, although it can also occur even when treatment is adequate . about 90% of acne scars are related with collagen loss (atrophic scars), whereas the remaining 10- 20% show collagen gain (keloidal or hypertrophic scars). resulting from the contraction of fibrous tissue, atrophic scars appear as depressions. atrophic acne scars can be classified into three distinct types: boxcar, icepick, and rolling.

Eligibility criteria:
inclusion criteria: patients aged equal or more than 18 years with atrophic post acne scars. exclusion criteria: pregnancy and lactation. hypertrophic scars. patients suffering from aggressive inflammatory acne. kidney or liver disease. active infection at site of lesion. patients use medications that reduce tissue healing during the study.
effect of fentanyl on coughing and recovery after anesthesia with an lma laryngeal mask airway)for airway management

Conditions: Ambulatory Surgery; Coughing

Summary: the purpose of this research is to evaluate the effectiveness of fentanyl for reducing coughing during the perioperative period (i.e., insertion of an lma \[laryngeal mask airway\] device, maintenance period during surgery, and awakening \[emergence\] from general anesthesia) for ambulatory surgery procedures. also to assess the effects of fentanyl on the postoperative outcomes, (e.g., pain, postoperative nausea and vomiting, return of bowel function \[constipation\], resumption of normal activities of daily living). fentanyl is one of the most common used anesthetic adjuncts for ambulatory surgery because of its anesthetic-sparing effects and alleged ability to reduce coughing during instrumentation of the patient's airway.

this research study is designed to evaluate the effects of fentanyl when administered as an adjuvant to standard anesthetic and analgesic drugs on coughing (during insertion of an lma device, during maintenance and emergence from general anesthesia) and on the postoperative adverse outcomes (i.e., side effects). all patients will receive local anesthetics and commonly used non-opioid pain relieving medications during surgery.

Eligibility criteria:
inclusion criteria * patients scheduled to undergo outpatient arthroscopic surgery procedures * willingness and ability to sign an informed consent document * no allergies to anesthetic or analgesic medications * 18 - 80 years of age * american society of anesthesiologists (asa) class i - iii adults of either sex * women of childbearing potential must be currently practicing an acceptable form of birth control, and have a negative urine pregnancy test exclusion criteria * patients with known allergy, hypersensitivity or contraindications to anesthetic or analgesic medications * patients with clinically-significant medical conditions, such as brain, heart, kidney, endocrine, or liver diseases, peptic ulcer disease or bleeding disorders * pregnant or lactating women * subjects with a history of alcohol or drug abuse within the past 3 months * any other conditions or use of any medication which may interfere with the conduct of the study (e.g., asthmatic patients history of asthma, chronic cough, or upper respiratory tract infection during the previous 2 wk or recent treatment with angiotensin-converting enzyme inhibitors, bronchodilators, or steroids.

Keywords: ambulatory surgery pain management perioperative outcomes fentanyl coughing during insertion of an lma ambulatory surgery procedures
neural and cognitive mechanisms of depression and anxiety: a multimodal mri study

Conditions: Depression

Summary: to explore the neural and cognitive mechanisms of depression (including unipolar depression and bipolar disorder) and anxiety using multimodal mri techniques.


Eligibility criteria:
inclusion criteria: * age range from 16 to 55 years old. * all patients were interviewed by two experienced psychiatrists using the structured clinical interview for dsm-iv (patient edition) exclusion criteria: * schizophrenia, mental retardation or personality disorder, any history of loss of consciousness, substance abuse, serious medical or neurological illness. * subjects with contraindications to mri

Keywords: depression anxiety disorder bipolar disorder magnetic resonance imaging
multimodal geriatric pre-authorization before scheduled orthopedic surgery

Conditions: Osteoarthritis; Gonarthrosis

Summary: the main objective of this multicentric, prospective and interventional study is to assess the feasibility of multimodal prehabilitation in patients aged 75 years or older with surgical indication for coxarthrosis or severe gonarthrosis

this study consists of a pre-established surgical preparation program in cooperation with physiotherapists or physical activity instructors, dieticians, psychologists, physical therapists and nurses. this innovative program improves muscle strength, balance and walking of the study patients. it also allows for faster and better recovery of their physical fitness and intellectual abilities after surgery. these interventions will be performed in day admission (da) and at home and will consist of training, a diet program to strengthen the muscles and balance of the patients participating in the study. patients who agree to participate in the study will receive interventions for 6 weeks prior to surgery, partly in a day hospital and partly at home, including: * muscle rehabilitation developed with a physiotherapist or physical activity instructor * nutritional support (dietician at 1st, 3rd, and 6th day admission (da), referring geriatrician) * cognitive and physical stimulation "exergame" (genious healthcare); with only cognitive exercises at home * psychological support by a psychologist * information in the form of videos on the main risks and important points to know and prepare before and after surgery * 1 follow-up call per week made by the pre4os referent between each day admission (da) to assess patient satisfaction, any limitations encountered, possible exercises at home, the occurrence of possible adverse effects * 1 hour per week home adapted physical activity session by the siel bleu association

Eligibility criteria:
inclusion criteria: * age ≥ 75 years * surgical indication for total hip or knee replacement for hip or knee osteoarthritis. * minimum time of 6 weeks between inclusion visit and date of surgery * physical (excluding coxarthrosis or knee osteoarthritis) and cognitive capacities to follow a prehabilitation program (assessment by the geriatrician) * proximity between place of life and hospital to go to the center for pre-rehabilitation * good understanding of the french language * benefiting from social coverage * have read the information notice and have consented to participate in the study by signing a written consent exclusion criteria: * urgent surgery (trauma, acute dislocation) * neurocognitive disorders at a moderate or severe stage (mini mental state examination (m.m.s.e) ≤20), or not evaluable and not allowing to participate in the prehabilitation program * lack of social coverage (beneficiary or beneficiary) * adult persons subject to a legal protection measure (curatorship, guardianship and safeguard of justice) * refusal to participate * hospitalized patients ( the living space can be the home or thelon term care).

Keywords: osteoarthritis gonarthrosis orthopaedic surgery
study of tamsulosin and/or dutasteride to relieve urinary symptoms after brachytherapy for localized prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine whether a drug named tamsulosin (flomax), or another drug named dutasteride (avodart), or a combination of these two drugs is effective in improving urinary symptoms and decreasing the rate of intermittent self-catheterization after prostate brachytherapy.

image-guided transperineal permanent prostate brachytherapy (pi) is an accepted curative treatment option for patients with early stage prostate cancer. the most severe side effect of pi is urinary retention requiring intermittent self-catheterization (isc). this study will assess the ability of pharmacologic intervention to ameliorate the post-operative side effect of pi. the use of both tamsulosin and dutasteride is proposed to have benefit in reducing urinary symptom score and in reducing the rate of intermittent self-catheterization for patients with prostate adenocarcinoma after prostate implant.

Eligibility criteria:
inclusion criteria: * patient is eligible for a prostate implant * patient is greater than 18 years of age * patient is able to give informed consent * patient does not currently take flomax, dutasteride or finasteride * patient does not have a known hypersensitivity reaction to flomax or dutasteride exclusion criteria: * patients who have a known hypersensitivity reaction to tamsulosin, dutasteride or finasteride and those patients who are already on any prior to prostate implantation * patients who are taking a pde-5 inhibitor including sildenafil (viagra), tadalafil (cialis) and vardenafil (levitra) are ineligible to participate unless they are willing to discontinue using those drugs one week prior to their implant and for three months after the implant

Keywords: brachytherapy urinary symptoms